98%
921
2 minutes
20
Direct, single molecule measurement of RNA by long-read transcriptome sequencing (LRTS) enables the reliable detection of transcripts and alternative splicing events, thus contributing to the identification of splicing mechanisms, improvement of current gene models, as well as to the prediction of more reliable protein isoforms. LRTS data comes from either PacBio's single-molecule real time sequencing or from Oxford Nanopore's nanopore sequencing. Previously, we developed IsoTools, a software originally designed for processing and analyzing PacBio data. IsoTools copes with the complexity of LRTS data and offers multiple functionality for transcript identification and quantification as well as the analysis of differential isoform usage and local differential splicing events. Here, we report an update of the software, IsoTools 2.0, and demonstrate its additional performance on Oxford Nanopore data from multiple experimental protocols. We present the IsoTools 2.0 workflow, highlighting novel functionalities with respect to reliable transcript detection as well as transcription start site prediction. Additionally, we show novel metrics for structural description and quantification of gene model variability based on the gene's transcripts. We demonstrate the performance of IsoTools 2.0 on a variety of experimental protocols for library construction from a recent LRTS challenge. We show that IsoTools 2.0 is able to cope with the inherent complexity of LRTS data and that the workflow generates meaningful hypotheses on biomarkers for alternative splicing. The software is available from https://github.com/HerwigLab/IsoTools2/.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jmb.2025.169049 | DOI Listing |
Hepatobiliary Surg Nutr
August 2025
Department of Surgery, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Background: The optimal timing of transplantation for hepatocellular carcinoma (HCC) is still under debate regarding the tumor biology and locoregional control with various treatments. We designed this study to find out what kind of factors affect the post-transplantation outcome focusing on the timing of transplantation.
Methods: We analyzed HCC patients who met the Milan criteria at the initial stage and subsequently underwent liver transplantation (LT) between 2007 and 2020.
Bioengineering (Basel)
August 2025
Department of Radiological Sciences, University of California, Los Angeles, CA 92521, USA.
Quantitative dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is emerging as a valuable tool for assessing tumor and parenchymal perfusion in the liver, playing a developing role in locoregional therapies (LRTs) for hepatocellular carcinoma (HCC). This review explores the conceptual underpinnings and early investigational stages of DCE-MRI for LRTs, including thermal ablation, transarterial chemoembolization (TACE), and transarterial radioembolization (TARE). Preclinical and early-phase studies suggest that DCE-MRI may offer valuable insights into HCC tumor microvasculature, treatment response, and therapy planning.
View Article and Find Full Text PDFAbdom Radiol (NY)
August 2025
DASA, São Paulo, Brazil.
The Liver Imaging Reporting and Data System (LI-RADS) has become an essential tool for standardizing the detection, diagnosis, and treatment response assessment of hepatocellular carcinoma (HCC) using contrast-enhanced CT and MRI. With the rising incidence of HCC, the use of local-regional therapies (LRT) has also expanded. To address the increasing complexity of post-treatment imaging interpretation, the LI-RADS Treatment Response Assessment (TRA) algorithm was developed to provide a structured and reproducible approach for evaluating tumor response following various forms of LRT.
View Article and Find Full Text PDFClin Transl Gastroenterol
June 2025
Division of Gastroenterology and Hepatology, University of California San Francisco, San Francisco, California, USA.
Introduction: It is unknown how frailty evolves over time in patients with hepatocellular carcinoma who are treated with locoregional therapies (LRTs).
Methods: We conducted a retrospective study of LRT-treated hepatocellular carcinoma patients with Liver Frailty Index (LFI) assessments. Linear mixed-effects modeling was used to assess the impact of time (modeled linearly per month) and other variables on LFI.
Cancers (Basel)
February 2025
Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
Background/objectives: Locoregional therapies (LRTs), including transarterial embolization (TAE), transarterial chemoembolization (TACE), and transarterial radioembolization (TARE), have become integral in the management of hepatocellular carcinoma (HCC) in recent decades and continue to shape evolving treatment strategies. While their role in liver tumor management is well established, their potential for treating extrahepatic malignancies is gaining increasing attention. Notably, growing research has highlighted the promising applications of TAE, TACE, and TARE in extrahepatic cancers such as glioblastoma (GBM), soft tissue sarcomas (STSs), prostate cancer (PCa), pancreatic cancer, and renal cell carcinoma (RCC).
View Article and Find Full Text PDF